Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NODE-202
NCT05763953Phase 2Recruiting
- Sponsor
- Milestone Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of etripamil in paroxysmal supraventricular tachycardia (PSVT), sponsored by Milestone Pharmaceuticals. Started Dec 2023; status: recruiting.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NCT05763953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05763953.